Long-term study of lebrikizumab in children with atopic dermatitis
Tests lebrikizumab over time in children aged 6 months to under 18 with eczema.
Plain-language title generated from the registry record
Registry title: A Study to Assess the Long-Term Safety and Efficacy of Lebrikizumab (LY3650150) in Participants 6 Months to <18 Years of Age With Moderate-to-Severe Atopic Dermatitis
Key facts
- Where
- Cracow, Gdansk, Lodz, and Warsaw, PolandSee the 4 sites
- Phase
- Phase 3
AI summary: who the study is looking for
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for children and teenagers with moderate-to-severe atopic dermatitis who already finished the earlier study KGBI and now continue lebrikizumab treatment.
- Age
- 6 Months to under 18 Years
- Sex
- All sexes can join.
- Disease stage
- Moderate-to-severe atopic dermatitis.
- Earlier treatment
- Must have been treated in study KGBI and completed its treatments and last visit, including any washout of systemic atopic dermatitis treatment.
Main reasons for not taking part
- A serious side effect in study KGBI judged related to lebrikizumab
- A side effect in study KGBI related to lebrikizumab that led to stopping treatment
- Met the criteria for permanent treatment stop in study KGBI, if related to lebrikizumab or led to withdrawal from the study
- Pregnant or breastfeeding, or planning to become pregnant or breastfeed during the study
Read by machine on 9 November 2026.
Where in Poland
- Diamond Clinic Sp. z o.o.Cracow, PolandNo longer taking part
- Centrum Badan Klinicznych PI-House sp. z o.o.Gdansk, PolandNo longer taking part
- DERMED Centrum Medyczne Sp. z o.o.Lodz, PolandNo longer taking part
- Evimed Sp. z o.o.Warsaw, PolandNo longer taking part
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorTrial details
- Who runs it
- Eli Lilly and Company
- Trial code
- NCT05735483EU 2022-501478-21-00
- Record updated
- 26 October 2026
- Original description
The main purpose of this study is to assess the long-term safety and efficacy of lebrikizumab in participants 6 Months to <18 years of age with moderate-to-severe atopic dermatitis.Read full original descriptionShow less
A Phase 3, Multicenter, Long-Term Extension Study to Assess the Safety and Efficacy of Lebrikizumab in Participants 6 Months to <18 Years of Age With Moderate-to-Severe Atopic Dermatitis
The main purpose of this study is to assess the long-term safety and efficacy of lebrikizumab in participants 6 Months to <18 years of age with moderate-to-severe atopic dermatitis.
This study will last about 68 weeks and may include up to 16 planned visits. If participating in the optional extension as well, the study will last approximately 1 additional year for a total of up to 116 weeks and may include up to 29 scheduled visits.
Inclusion: Received treatment in Study KGBI and have adequately completed the study treatments and last visit of study KGBI, including any applicable systemic AD treatment washout; For female participants of childbearing potential, highly effective contraceptive use should be consistent with local regulations regarding the methods of contraception for those participating in clinical studies.
Exclusion: Developed an serious adverse events (SAE) during their participation in parent study KGBI deemed related to lebrikizumab, which in the opinion of the investigator or of the medical monitor could indicate that continued treatment with lebrikizumab may present an unreasonable risk for the participant; Developed an AE during their participation in the study KGBI that was deemed related to lebrikizumab and led to study treatment discontinuation, which in the opinion of the investigator or of the medical monitor could indicate that continued treatment with lebrikizumab may present an unreasonable risk for the participant; Met the criteria for permanent study intervention discontinuation in study KGBI, if deemed related to lebrikizumab or led to investigator- or sponsor-initiated withdrawal of participant from the study (for example, noncompliance, inability to complete study assessments, etc.); Note: If study KGBI is still blinded at the time of rollover to study KGBJ, conditions deemed related to the study treatment will be considered related to lebrikizumab; Are pregnant or breastfeeding or are planning to become pregnant or breastfeed during the study.